Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to $9.7 million.

  • Roivant Sciences' Gains from Investment Securities rose 115555.56% to $9.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.6 million, marking a year-over-year decrease of 11460.65%. This contributed to the annual value of $61.9 million for FY2025, which is 47548.52% up from last year.
  • Per Roivant Sciences' latest filing, its Gains from Investment Securities stood at $9.7 million for Q4 2025, which was up 115555.56% from -$6.0 million recorded in Q3 2025.
  • Over the past 5 years, Roivant Sciences' Gains from Investment Securities peaked at $444.6 million during Q3 2021, and registered a low of -$11.1 million during Q2 2025.
  • Over the past 5 years, Roivant Sciences' median Gains from Investment Securities value was $774000.0 (recorded in 2024), while the average stood at $61.3 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 68532.22% in 2022, then soared by 115555.56% in 2025.
  • Roivant Sciences' Gains from Investment Securities (Quarter) stood at $443.8 million in 2021, then plummeted by 98.18% to $8.1 million in 2022, then skyrocketed by 294.82% to $31.8 million in 2023, then crashed by 97.57% to $774000.0 in 2024, then soared by 1155.56% to $9.7 million in 2025.
  • Its Gains from Investment Securities stands at $9.7 million for Q4 2025, versus -$6.0 million for Q3 2025 and -$11.1 million for Q2 2025.